Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00929110
Registration number
NCT00929110
Ethics application status
Date submitted
25/06/2009
Date registered
26/06/2009
Date last updated
17/08/2012
Titles & IDs
Public title
1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
Query!
Scientific title
A 52-week Treatment, Randomized, Double-blind, Placebo-controlled, With Open-label Tiotropium, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Patients With Chronic Obstructive Pulmonary Disease
Query!
Secondary ID [1]
0
0
2008-008394-63
Query!
Secondary ID [2]
0
0
CNVA237A2303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
GLOW2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Glycopyrronium bromide
Treatment: Drugs - Placebo to glycopyrronium bromide
Treatment: Drugs - Tiotropium
Experimental: Glycopyrronium bromide 50 µg - Patients inhaled glycopyrronium bromide 50 µg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting ß2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Placebo comparator: Placebo to glycopyrronium bromide - Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting ß2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Active comparator: Tiotropium 18 µg - Patients inhaled tiotropium 18 µg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting ß2-agonist salbutamol/albuterol was available for rescue use throughout the study.
Treatment: Drugs: Glycopyrronium bromide
Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Treatment: Drugs: Placebo to glycopyrronium bromide
Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Treatment: Drugs: Tiotropium
Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Query!
Assessment method [1]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included baseline FEV1 measurement, baseline inhaled corticosteroid use (Yes/No), FEV1 prior to inhalation of short-acting ß2 agonist (SABA), and FEV1 45 min post-inhalation of SABA as covariates.
Query!
Timepoint [1]
0
0
Week 12
Query!
Secondary outcome [1]
0
0
Transition Dyspnea Index (TDI) at Week 26
Query!
Assessment method [1]
0
0
The TDI measured changes in dyspnea from baseline during treatment and included 3 domains: Functional impairment (activities of daily living), magnitude of task (intensity of activity), and magnitude of effort (difficulty breathing). Each domain was rated from -3 to 3 (major deterioration-major improvement). The total score ranged from -9 to 9; minus scores indicate deterioration. The analysis included the same covariates as the primary Outcome Measure.
Query!
Timepoint [1]
0
0
Week 26
Query!
Secondary outcome [2]
0
0
Health-related Quality of Life (QoL) Assessed With the St. George Respiratory Questionnaire (SGRQ) at Week 52
Query!
Assessment method [2]
0
0
The SGRQ contained 51 patient-rated items divided into three components: Symptoms (respiratory symptoms, their frequency, and severity), Activity (activities that cause or are limited by breathlessness), and Impacts (social functioning and psychological disturbances resulting from airway disease). A total score for the 3 components was calculated and ranged from 0 to 100. Higher values indicate greater impairment of QoL. The analysis included the same covariates as the primary Outcome Measure.
Query!
Timepoint [2]
0
0
Week 52
Query!
Secondary outcome [3]
0
0
Time to First Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)
Query!
Assessment method [3]
0
0
Time to first moderate or severe COPD exacerbation was calculated as the number of days from baseline to the day on which the patient experienced the first moderate or severe COPD exacerbation. A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.
Query!
Timepoint [3]
0
0
Baseline to Week 52 (patients with no moderate or severe exacerbations who completed the study were censored at the final visit date, which may have exceeded 52 weeks)
Query!
Secondary outcome [4]
0
0
Change From Baseline in the Mean Daily Number of Puffs of Rescue Medication Taken During the Study (Baseline to Week 52)
Query!
Assessment method [4]
0
0
The number of puffs of rescue medication taken in the previous 12 hours was recorded in the Patient Diary in the morning and evening. The mean daily number of puffs of rescue medication taken was calculated by dividing the number of puffs of rescue medication per day over the 52 weeks of the study by the number of days with non-missing rescue medication data. Rescue medication data recorded during the 14 day run-in period was used to calculate the baseline. The analysis included the same covariates as the primary Outcome Measure. A positive change score indicates more puffs taken.
Query!
Timepoint [4]
0
0
Baseline to Week 52
Query!
Secondary outcome [5]
0
0
Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1, Week 26, and Week 52
Query!
Assessment method [5]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose. The analysis included the same covariates as the primary Outcome Measure.
Query!
Timepoint [5]
0
0
Day 1, Week 26, and Week 52
Query!
Secondary outcome [6]
0
0
Trough Forced Vital Capacity (FVC) at Day 1, Week 12, Week 26, and Week 52
Query!
Assessment method [6]
0
0
Trough FVC is defined as the average of the post-dose 23 h 15 min and the 23 h 45 min FVC values. Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told "At the end of the next normal breath out, take a deep breath all the way in"; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure.
Query!
Timepoint [6]
0
0
Day 1, Week 12, Week 26, and Week 52
Query!
Secondary outcome [7]
0
0
Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Query!
Assessment method [7]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.
Query!
Timepoint [7]
0
0
5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Query!
Secondary outcome [8]
0
0
Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; 1, 2, 3, 4, 6, 8, 10, and 12 Hours; 23 Hours 15 Minutes; and 23 Hours 45 Minutes Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Query!
Assessment method [8]
0
0
Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told "At the end of the next normal breath out, take a deep breath all the way in"; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.
Query!
Timepoint [8]
0
0
5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Query!
Secondary outcome [9]
0
0
Forced Expiratory Volume in 1 Second (FEV1) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post Dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Query!
Assessment method [9]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.
Query!
Timepoint [9]
0
0
5, 15, and 30 minutes; and 1, 2, 3, 4 hours post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Query!
Secondary outcome [10]
0
0
Forced Vital Capacity (FVC) 5, 15, and 30 Minutes; and 1, 2, 3, and 4 Hours Post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Query!
Assessment method [10]
0
0
Just prior to FVC measurement, patients performed normal tidal breathing. The patient was given a few breaths warning before being told "At the end of the next normal breath out, take a deep breath all the way in"; they were then verbally encouraged to make a maximal effort before relaxing. The analysis included the same covariates as the primary Outcome Measure. Data was not collected at all time points for all Days and Weeks.
Query!
Timepoint [10]
0
0
5, 15, and 30 minutes; and 1, 2, 3, 4 hours post-dose at Days 1 and 15; and Weeks 5, 9, 12, 16, 20, 26, 34, 42, 50, and 52
Query!
Secondary outcome [11]
0
0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at Day 1 and Weeks 12, 26, and 52
Query!
Assessment method [11]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 3, and 4 hours post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.
Query!
Timepoint [11]
0
0
From 5 minutes to 4 hours post-dose at Day 1 and Weeks 12, 26, and 52
Query!
Secondary outcome [12]
0
0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 12 Hours Post-dose at Day 1 and Weeks 12 and 52
Query!
Assessment method [12]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; and 1, 2, 3, 4, 6, 8 10, and 12 hours post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.
Query!
Timepoint [12]
0
0
From 5 minutes to 12 hours post-dose at Day 1 and Weeks 12 and 52
Query!
Secondary outcome [13]
0
0
Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 23 Hours 45 Minutes and From 12 Hours to 23 Hours 45 Minutes Post-dose at Weeks 12 and 52
Query!
Assessment method [13]
0
0
FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made at 5, 15, and 30 minutes; 1, 2, 3, 4, 6, 8, 10, and 12 hours; 23 hours 15 minutes; and 23 hours 45 minutes post-dose. Standardized FEV1 AUC was calculated by the trapezoidal rule. The analysis included the same covariates as the primary Outcome Measure.
Query!
Timepoint [13]
0
0
From 5 minutes to 23 hours 45 minutes post-dose at Weeks 12 and 52
Query!
Secondary outcome [14]
0
0
Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Per Year During the Study (Baseline to Week 52)
Query!
Assessment method [14]
0
0
The number of moderate or severe exacerbations of COPD per year during the study was calculated by dividing the total number of exacerbations during the study by the total number of years of treatment. A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.
Query!
Timepoint [14]
0
0
Baseline to Week 52
Query!
Secondary outcome [15]
0
0
Percentage of Patients Who Experienced a Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation During the Study (Baseline to Week 52)
Query!
Assessment method [15]
0
0
A COPD exacerbation was considered to be moderate if treatment with systemic corticosteroids and/or antibiotic was required. A COPD exacerbation was considered to be severe if treatment for moderate severity and hospitalization was required.
Query!
Timepoint [15]
0
0
Baseline to Week 52
Query!
Secondary outcome [16]
0
0
Percentage of Nights With "no Nighttime Awakenings" During the Study (Baseline to Week 52)
Query!
Assessment method [16]
0
0
A night with "no nighttime awakenings" was defined as any night where the patient did not wake up due to 1 or more of 6 symptoms (respiratory symptoms, cough, wheeze, amount of sputum, color of sputum, and breathlessness). Symptoms occurring during the previous 12 hours were recorded each morning and evening by the patient in an electronic diary. The percentage of nights with 'no nighttime awakenings' was calculated as the total number of nights with "no nighttime awakenings" over the 52 week treatment period divided by the total number of nights where diary recordings were made.
Query!
Timepoint [16]
0
0
Baseline to Week 52
Query!
Secondary outcome [17]
0
0
Percentage of Days With "no Daytime Symptoms" During the Study (Baseline to Week 52)
Query!
Assessment method [17]
0
0
A day with "no daytime symptoms" was defined as any day where the patient recorded no cough, no wheeze, no production of sputum, no feeling of breathlessness (other than when running), and no puffs of rescue medication during the previous 12 hours in evening entry in the electronic patient diary. The percentage of days with "no daytime symptoms" was calculated as the total number of days with "no daytime symptoms" over the 52 week treatment period divided by the total number of days where diary recordings were made.
Query!
Timepoint [17]
0
0
Baseline to Week 52
Query!
Secondary outcome [18]
0
0
Percentage of "Days Able to Perform Usual Daily Activities" During the Study (Baseline to Week 52)
Query!
Assessment method [18]
0
0
A "day able to perform usual daily activities" was defined as any day where the patient recorded in their electronic diary in the evening that they were not prevented from performing their usual daily activities due to respiratory symptoms during the previous 12 hours. The percentage of "days able to perform usual daily activities" was calculated as the total number of "days able to perform usual daily activities" over the 52 week treatment period divided by the total number of days where diary recordings were made.
Query!
Timepoint [18]
0
0
Baseline to Week 52
Query!
Secondary outcome [19]
0
0
Change From Baseline in the Mean Daily Total Symptom Score During the Study (Baseline to Week 52)
Query!
Assessment method [19]
0
0
The daily total symptom score was defined as the sum of the morning and evening patient self-reported diary assessments of 6 symptoms (respiratory symptoms/impact on daily activities, cough, wheeze, amount of sputum, color of sputum, and breathlessness). Means for baseline (14 day maximum run-in period) and the 52 week treatment period were calculated. Mean scores ranged from 0-18, with a higher score indicating worse symptoms. A negative change score indicated improvement.
Query!
Timepoint [19]
0
0
Baseline to Week 52
Query!
Eligibility
Key inclusion criteria
1. Male or female adults aged = 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure.
2. Patients with moderate to severe stable chronic obstructive pulmonary disease (COPD, Stage II or Stage III) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.
3. Current or ex-smokers who have a smoking history of at least 10 pack years.
4. Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) = 30% and < 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity (FVC) < 0.7 at Visit 2 (Day -14).
5. Patients, according to daily electronic diary data between Visit 2 (Day -14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to Visit 3 (Day 1).
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy test).
2. Women of child-bearing potential, unless using an approved method of medical or surgical contraception.
3. Patients requiring long term oxygen therapy (> 15 h a day) on a daily basis for chronic hypoxemia, or who have been hospitalized for an exacerbation of their airways disease in the 6 weeks prior to Visit 1 (Day -21) or between Visit 1 (Day -21) and Visit 3 (Day 1).
4. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1 (Day -21).
5. Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition.
6. Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count > 600/mm^3 (at Visit 1, Day -21) and onset of symptoms prior to age 40 years.
7. Patients with a history of long QT syndrome or whose QTc measured at Visit 1 (Day -21) (Fridericia method) is prolonged (> 450 ms for males or > 470 ms for females.
Other protocol-defined inclusion/exclusion criteria may apply to the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1066
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Kentucky
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Louisiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maine
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Maryland
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Massachusetts
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Minnesota
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Missouri
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Montana
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Nebraska
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
New Jersey
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
New York
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
North Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Ohio
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oklahoma
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Oregon
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Pennsylvania
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Rhode Island
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
South Carolina
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Texas
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Utah
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Washington
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Wisconsin
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Buenos Aires
Query!
Country [36]
0
0
Argentina
Query!
State/province [36]
0
0
Capital Federal
Query!
Country [37]
0
0
Argentina
Query!
State/province [37]
0
0
La Plata - Bueno Aire
Query!
Country [38]
0
0
Argentina
Query!
State/province [38]
0
0
Parana Entre Rios
Query!
Country [39]
0
0
Argentina
Query!
State/province [39]
0
0
Rosario
Query!
Country [40]
0
0
Argentina
Query!
State/province [40]
0
0
Tucuman
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Brampton
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Calgary
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Edmonton
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Kelowna
Query!
Country [45]
0
0
Canada
Query!
State/province [45]
0
0
Langley
Query!
Country [46]
0
0
Canada
Query!
State/province [46]
0
0
Niagara Falls
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Quebec
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Ste-Foy
Query!
Country [49]
0
0
Chile
Query!
State/province [49]
0
0
Santiago
Query!
Country [50]
0
0
Chile
Query!
State/province [50]
0
0
Talcahuano
Query!
Country [51]
0
0
Chile
Query!
State/province [51]
0
0
Vina del Mar
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Dijon
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Paris
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Rennes Cedex
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Berlin
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Landsberg
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Muenchen
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Munich
Query!
Country [59]
0
0
Hungary
Query!
State/province [59]
0
0
Gyonsyos
Query!
Country [60]
0
0
Hungary
Query!
State/province [60]
0
0
Siokok
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Be'er Sheva
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Haifa
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Jerusalem
Query!
Country [64]
0
0
Israel
Query!
State/province [64]
0
0
Kfar Saba
Query!
Country [65]
0
0
Israel
Query!
State/province [65]
0
0
Rehovot
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Firenze
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Monza
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Parma
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Busan
Query!
Country [70]
0
0
Korea, Republic of
Query!
State/province [70]
0
0
Gyeonggi-go
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Incheon
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Seoul
Query!
Country [73]
0
0
Mexico
Query!
State/province [73]
0
0
Guadalajara
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Monterrey
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
San Luis Potosi
Query!
Country [76]
0
0
Netherlands
Query!
State/province [76]
0
0
Sneek
Query!
Country [77]
0
0
New Zealand
Query!
State/province [77]
0
0
Auckland
Query!
Country [78]
0
0
New Zealand
Query!
State/province [78]
0
0
Christchurch
Query!
Country [79]
0
0
New Zealand
Query!
State/province [79]
0
0
Hamilton
Query!
Country [80]
0
0
New Zealand
Query!
State/province [80]
0
0
Tauranga
Query!
Country [81]
0
0
New Zealand
Query!
State/province [81]
0
0
Wellington
Query!
Country [82]
0
0
Peru
Query!
State/province [82]
0
0
Lima
Query!
Country [83]
0
0
Peru
Query!
State/province [83]
0
0
Santiago de Surco
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Bialystok
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Bydgoszcz
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Bystra
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Gdansk
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Krakow
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Ostrow Wielkopolski
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Piekary Slaskic
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Tarnow
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Warszawa
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Barnaul
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Irkutsk
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Moscow
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Smolensk
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Volgograd
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Yaroslavl
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00929110
Query!
Trial related presentations / publications
D'Urzo A, Kerwin E, Overend T, D'Andrea P, Chen H, Goyal P. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin. 2014 Mar;30(3):493-508. doi: 10.1185/03007995.2013.858618. Epub 2013 Nov 19. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012 Nov;40(5):1106-14. doi: 10.1183/09031936.00040712. Epub 2012 Jul 26.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00929110
Download to PDF